Lifesign Status COVID-19/Flu A&B Rapid Immunoassay – 25 Tests per Box
The Lifesign Status COVID-19/Flu A&B Rapid Immunoassay is a FDA Emergency Use Authorized (EUA) rapid test designed for the simultaneous, direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A, and Influenza Type B antigens. Ideal for point-of-care use, this test detects viral antigens from anterior nasal and nasopharyngeal swab specimens with reliable accuracy.
Delivering clear, visually interpretable results within 15 minutes, the assay utilizes flocked nasopharyngeal swabs engineered for superior specimen collection and enhanced patient comfort. The test’s high sensitivity and specificity provide confidence in clinical decision-making for respiratory illness management.
Performance:
-
COVID-19 Anterior Nasal Swab: Sensitivity 93.8%, Specificity 100%
-
COVID-19 Nasopharyngeal Swab: Sensitivity 93.1%, Specificity 100%
-
Influenza A: Sensitivity 91.4%, Specificity 95.7%
-
Influenza B: Sensitivity 87.6%, Specificity 95.9%
Kit Contents:
-
25 test devices
-
25 extraction reagent capsules
-
25 sterile swabs
-
1 positive control swab
-
1 negative control swab
-
Package insert with detailed instructions
-
Quick reference guide for ease of use
This rapid immunoassay enables healthcare providers to quickly differentiate between COVID-19 and flu infections, facilitating timely and appropriate patient care. Its ease of use, combined with reliable accuracy, makes it an essential tool for clinics, urgent care centers, and testing sites.
